Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
This protein carries a polyhistidine tag at the C-terminus.
This protein contains a furin convertase cleavage site, 737-RKRR-740, and will be partially processed into N (α chain) and C-terminal fragment (partial β chain) with calculated MW of 81.0 kDa and 23.8 kDa respectively. The protein migrates as 35-45 kDa (partial β chain), 110-120 kDa (α chain) and 130 kDa (α chain & partial β chain) under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human IGF-I R, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
The purity of Human IGF-I R, His Tag (Cat. No. IGR-H5229) is more than 90% and the molecular weight of this protein is around 252-308 kDa verified by SEC-MALS.
Immobilized Human IGF-I R, His Tag (Cat. No. IGR-H5229) at 5 μg/mL (100 μL/well) can bind Human IGF-I, Fc Tag with a linear range of 0.01-0.625 μg/mL (QC tested).
Human IGF-I R, His Tag (Cat. No. IGR-H5229) immobilized on CM5 Chip can bind Biotinylated Human IGF-I, His,Avitag (Cat. No.IG1-H82Q6) with an affinity constant of 68 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Human IGF-I R, His Tag (Cat. No. IGR-H5229) captured on CM5 chip via anti-His antibody can bind Human IGF-I, Fc Tag (Cat. No. IG1-H4269) with an affinity constant of 0.189 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Human IGF-I R, His Tag (Cat. No. IGR-H5229) immobilized on CM5 Chip can bind Biotinylated Human IGF-II, His,Avitag with an affinity constant of 51.2 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Fecha | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Mecasermin (Astellas/OrphanPacific) | Approved | Astellas Pharma Inc | Somazon | Japan | Growth hormone deficiency; Dwarfism; Diabetes Mellitus, Lipoatrophic | null | 1994-10-05 | HIV Infections; Diabetes Mellitus, Lipoatrophic; Heart Failure; Myocardial Infarction; Multiple Sclerosis; Lipodystrophy; Dwarfism; Growth hormone deficiency | Details | |
Mecasermin (Ipsen) | IGF-1; FK-780; MKN-031 | Approved | Ipsen | Increlex | United States | Failure to Thrive | Ipsen Inc | 2005-08-30 | Failure to Thrive; Autism Spectrum Disorder; X-Linked Combined Immunodeficiency Diseases; Phelan-McDermid syndrome; Growth Disorders; Muscular Dystrophy, Duchenne; Laron Syndrome | Details |
Brigatinib | AP-26113 | Approved | Ariad Pharmaceuticals Inc | Alunbrig, ALUNBRIG | United States | Carcinoma, Non-Small-Cell Lung | Takeda Pharmaceuticals U.S.A. Inc | 2017-04-28 | Solid tumours; Ependymoma; Carcinoma; Neoplasms; Neurofibromatosis 2; Small Cell Lung Carcinoma; Myofibroma; Lymphoma, Large-Cell, Anaplastic; Brain metastases; Lung Neoplasms; Granuloma, Plasma Cell; Carcinoma, Non-Small-Cell Lung; Sarcoma, Kaposi; Neurilemmoma; Meningioma; Neuroma, Acoustic | Details |
IGF-1 (Biogen/Pharmacia & Upjohn) | Approved | Biogen Inc, Pharmacia & Upjohn | Igef | Sweden | Dwarfism | null | 1994-01-01 | Dwarfism | Details | |
Ceritinib | LDK-378; NVP-LDK378; NVP-LDK378-NX | Approved | Novartis Pharma Ag | 赞可达, Zykadia | EU | Carcinoma, Non-Small-Cell Lung | Novartis Europharm Ltd | 2014-04-29 | Colorectal Neoplasms; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Brain metastases; Esophageal adenocarcinoma; Granuloma, Plasma Cell; Lymphoma, Large-Cell, Anaplastic; Hematologic Neoplasms; Hepatic Insufficiency; Cholangiocarcinoma; Pancreatic Neoplasms; Thyroid Carcinoma, Anaplastic; Neoplasms; Glioblastoma; Stomach Neoplasms | Details |
Teprotumumab | R-1507; RG-1507; RO-4858696; HZN-001 | Approved | Genmab A/S, F. Hoffmann-La Roche Ltd | Tepezza | United States | Graves Ophthalmopathy | Horizon Therapeutics Ireland | 2020-01-21 | Neoplasms; Graves Ophthalmopathy; Sarcoma; Breast Neoplasms; Diabetic macular oedema; Scleroderma, Diffuse; Carcinoma, Non-Small-Cell Lung | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Veligrotug | ZB-001; VRDN-001; AVE-1642 | Phase 3 Clinical | Viridian Therapeutics Inc | Solid tumours; Graves Ophthalmopathy; Multiple Myeloma; Breast Neoplasms | Details |
Teprotumumab biosimilar(Innovent) | IBI-311 | Phase 3 Clinical | Innovent Biologics(Suzhou) Co Ltd | Graves Ophthalmopathy | Details |
Ganitumab | AMG-479 | Phase 3 Clinical | Amgen Inc | Breast Neoplasms; Neuroectodermal Tumors, Primitive, Peripheral; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms; Lymphoma; Rhabdomyosarcoma, Alveolar; Lung Neoplasms; Colorectal Neoplasms; Neuroectodermal Tumors, Primitive; Prostatic Neoplasms; Sarcoma; Sarcoma, Ewing; Bone metastases; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Colonic Neoplasms; Rectal Neoplasms; Carcinoid Tumor; Rhabdomyosarcoma, Embryonal; Ovarian Neoplasms; Rhabdomyosarcoma; Solid tumours; Intestinal Neoplasms | Details |
Linsitinib | OSI-906; ASP-7487; OSI-906AA | Phase 3 Clinical | Astellas Pharma Inc, National Cancer Institute | Multiple Myeloma; Paraganglioma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Orbital Diseases; Eye Diseases; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Exophthalmos; Breast Neoplasms; Prostatic Neoplasms; Sarcoma, Ewing; Adrenocortical Carcinoma; Thyroid Diseases; Graves Ophthalmopathy; Endocrine System Diseases; Skin Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Hashimoto Disease; Head and Neck Neoplasms; Ovarian Neoplasms; Carney Complex; Liver Neoplasms; Solid tumours; Chondrosarcoma | Details |
Conteltinib | CT-707; SY-707 | Phase 3 Clinical | Shouyao Holding (Beijing) Co Ltd, Beijing Centaurus Biopharma Co Ltd | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
FPI-1434 | [225Ac]-FPI-1434; FPX-01 | Phase 2 Clinical | Fusion Pharma | Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Neoplasms; Adrenocortical Carcinoma; Uveal melanoma; Breast Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms | Details |
Dalotuzumab | h7C-10; MK-0646; F-50-035 | Phase 2 Clinical | Pierre Fabre Group | Solid tumours; Rectal Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Neuroendocrine Tumors; Multiple Myeloma; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung | Details |
CT-102 | CT-102 | Phase 2 Clinical | Hangzhou Tianlong Pharmaceutical Co Ltd, Institute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical Sciences | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
lonigutamab ugodotin | W-0101 | Phase 2 Clinical | Pierre Fabre Group | Solid tumours | Details |
Mecasermin Rinfabate | OHB-607; SHP-607; HGT-ROP-001; rhIGF-I/rhIGFBP-3; TAK-607 | Phase 2 Clinical | Insmed | Noonan Syndrome; Failure to Thrive; Cerebral Intraventricular Hemorrhage; Bronchopulmonary Dysplasia; Myotonic Dystrophy; Retinopathy of Prematurity; Muscular Dystrophies; Laron Syndrome | Details |
MHB018A | Phase 2 Clinical | Minghui Pharmaceutical (Hangzhou) Co Ltd | Graves Ophthalmopathy | Details | |
Lonigutamab | VB-421 | Phase 2 Clinical | Pierre Fabre Group | Graves Ophthalmopathy | Details |
Cixutumumab | A-12; IMC-A12; LY-3012217; NSC-742460 | Phase 2 Clinical | Eli Lilly And Company | Gastrinoma; Adenocarcinoma, Bronchiolo-Alveolar; Gliosarcoma; Colorectal Neoplasms; Neuroblastoma; Medullary thyroid cancer (MTC); Chondrosarcoma, Extraskeletal Myxoid; Retinoblastoma; Neurofibrosarcoma; Brain Stem Neoplasms; Lymphoma, Mantle-Cell; Breast Neoplasms; Osteosarcoma; Prostatic Neoplasms; Sarcoma; Sarcoma, Ewing; Liposarcoma; Esophageal adenocarcinoma; Neuroectodermal Tumors, Primitive, Peripheral; Adenocarcinoma; Melanoma; Paraganglioma; Breast Neoplasms, Male; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Sarcoma, Alveolar Soft Part; Adrenocortical Carcinoma; Rhabdomyosarcoma, Alveolar; Carcinoma, Neuroendocrine; Glioma; Esophageal Squamous Cell Carcinoma; Hemangiopericytoma; Lung Neoplasms; Pinealoma; Rectal Neoplasms; Carcinoma, Merkel Cell; Stomach Neoplasms; Hemangiosarcoma; Insulinoma; Hepatoblastoma; Esophageal Neoplasms; Mesenchymoma; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma, Embryonal; Carcinoma; Fibrosarcoma; Kidney Neoplasms; Liver Neoplasms; Head and Nec | Details |
Picropodophyllin | PPP; AXL-1717; NSC-36407 | Phase 2 Clinical | Axelar Ab | Astrocytoma; Carcinoma, Non-Small-Cell Lung | Details |
NNC0268-0965 | NNC0268-0965 | Phase 1 Clinical | Novo Nordisk A/S | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details |
IGF-1 receptor oligodeoxynucleotide-based immunotherapy (Thomas Jefferson University) | Phase 1 Clinical | Sidney Kimmel Cancer Center | Glioma | Details | |
Insulin-Like Growth Factor 1 (Wright State Physicians) | Phase 1 Clinical | Wright State Physicians | Nasolabial fold wrinkles; Burns; Sunburn | Details | |
SAR-446159 | ABL-301; SAR-446159 | Phase 1 Clinical | Abl Bio Inc | Parkinson Disease | Details |
VRDN-003 | VRDN-003 | Phase 1 Clinical | Viridian Therapeutics Inc | Graves Ophthalmopathy | Details |
VRDN-002 | VRDN-002 | Phase 1 Clinical | Viridian Therapeutics Inc | Graves Ophthalmopathy | Details |
LX-101 (Lirum Therapeutics) | 765IGF-MTX; IGF/MTX | Phase 1 Clinical | Lirum Therapeutics Inc | Head and Neck Neoplasms; Anemia, Refractory, with Excess of Blasts; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Neoplasms; Graves Ophthalmopathy; Breast Neoplasms; Brain Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Melanoma; Gastrointestinal Neoplasms | Details |
ZB-011 | ZB-011; ZB011 | Phase 1 Clinical | Viridian Therapeutics Inc | Graves Ophthalmopathy | Details |
Teprotumumab(Zhejiang Boxiao Bio-pharma) | Phase 1 Clinical | Zhejiang Boxiao Bio-pharmaceutical Co Ltd | Graves Ophthalmopathy | Details | |
PHP-1003 | PHP-1003; PHP1003 | Phase 1 Clinical | Suzhou Pulekang Pharmaceutical Technology Co Ltd | Graves Ophthalmopathy | Details |
124I-CPD-1023-figitumumab | 124I-CPD-1028; 125I-CPD-1028; CPD-1028-[124I]; CPD-1028-[125I]; FPX-1028 | Phase 1 Clinical | Fusion Pharma | Neoplasms | Details |
This web search service is supported by Google Inc.